--- title: "Relmada Therapeutics regains compliance with Nasdaq $1.00 bid price rule" url: "https://aibio.space/news/relmada-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-09-16" section: "Listings" tickers: "NASDAQ:RLMD" source: "https://www.sec.gov/Archives/edgar/data/1553643/000121390025087926/ea025749701ex99-1_relmada.htm" summary: "Relmada Therapeutics said on September 16, 2025 that Nasdaq confirmed in a September 15 notice that it has regained compliance with the $1.00 minimum bid p" --- By the aibio.space news desk. Sources - [Relmada Therapeutics, Inc. 8-K (2025-09-16)](https://www.sec.gov/Archives/edgar/data/1553643/000121390025087926/ea025749701ex99-1_relmada.htm) - [Relmada Therapeutics, Inc. 10-K (2025-03-27): business](https://www.sec.gov/Archives/edgar/data/1553643/000101376225003426/ea0229064-10k_relmada.htm) [RLMD](https://aibio.space/companies/relmada-therapeutics/) 2025-09-16 # Relmada Therapeutics regains compliance with Nasdaq $1.00 bid price rule Tickers [RLMD](https://aibio.space/companies/relmada-therapeutics/) Relmada Therapeutics said on September 16, 2025 that Nasdaq confirmed in a September 15 notice that it has regained compliance with the $1.00 minimum bid price. The stock stays on the Nasdaq Capital Market under RLMD, but the company's lead drug failed in late 2024. ## Key facts - **Company**: Relmada Therapeutics, Inc. (NASDAQ: RLMD) - **News type**: Listings - **Primary source**: [Relmada Therapeutics, Inc. 8-K (2025-09-16)](https://www.sec.gov/Archives/edgar/data/1553643/000121390025087926/ea025749701ex99-1_relmada.htm) *The White House and its lawn. CC0, via rawpixel. The picture shows the field, not the companies named.* ### The notice Relmada Therapeutics, Inc. received written notice from The Nasdaq Stock Market LLC on September 15, 2025 confirming that it has regained compliance with the $1.00 minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2). The company announced the notice in a release dated September 16, 2025, and filed it in an 8-K. To cure the problem, the shares had to hold a minimum closing bid price of $1.00 for at least 10 consecutive business days. The company says that test was met on September 12, 2025. Nasdaq has then closed the matter. Relmada says it is in full compliance with all of Nasdaq's continued listing requirements, and that its stock will keep trading on the Nasdaq Capital Market under RLMD. ### The setback behind the stock The compliance notice follows a difficult stretch. In its annual report, Relmada says its lead candidate, esmethadone, also known as d-methadone or REL-1017, was the subject of a pre-planned interim analysis of the Reliance II Phase 3 study in adjunctive major depressive disorder. In December 2024 the independent data monitoring committee found the study futile, unlikely to meet its primary efficacy endpoint with statistical significance. Relmada said it would pause both the Reliance II and Relight Phase 3 studies of esmethadone. The company attributes the 2024 result mostly to an overwhelming placebo response, which it says has become more common than exceptional in central nervous system trials. The program is paused pending a comprehensive data review, after which the company will decide its future. The company describes the review as a strategic move. It says it concluded that the most promising path to shareholder value was to acquire new development candidates while pausing work on REL-1017. The filing does not say what the review has found so far, and it gives no date for the decision. ### The replacement pipeline Relmada announced on March 25, 2025 an in-license from Trigone Pharma Ltd. of NDV-01, a novel delivery formulation of a widely used chemotherapy regimen for non-muscle-invasive bladder cancer. The annual report describes NDV-01 as in Phase 2. On February 6, 2025 it announced the acquisition of Sepranolone from Asarina Pharma AB, which it calls a Phase 2b-ready neurosteroid. The company names possible uses in Prader-Willi syndrome, Tourette syndrome and essential tremor, and in other diseases linked to excessive GABAergic activity. The annual report also lists REL-P11, a modified-release formulation of psilocybin that the company had been developing for metabolic disease. The program completed a Phase 1 safety study, but it is now paused. The filing cites a strategic review of that opportunity, the changing regulatory landscape for psychedelics, and the early stage of the program. The new candidates are at Phase 2 or earlier. The annual report listed milestones to come: NDV-01 Phase 2a data at the 2025 American Urological Association meeting in the first half of 2025, U.S. investigational new drug clearance in the second half of 2025, and a Sepranolone trial start in Prader-Willi syndrome by year-end 2025. The September release gives no update on any of them. It lists among its risks a failure to secure FDA agreement on the regulatory path for NDV-01 and sepranolone, and a failure to secure adequate drug supply. ### What the notice does not settle Regaining the bid price is a listing matter, not a clinical one. The notice confirms that the closing price cleared $1.00 for 10 business days, and nothing more. It does not say whether the stock will stay above $1.00, and it does not tell investors anything about the cash the company holds or the cost of the new programs. The company's own description of its strategy names innovation, unmet medical need, large markets and intellectual property. Those are goals rather than results, and the filing gives no data for any of the new candidates beyond the Phase 1 safety study of REL-P11. ### What comes next Relmada says it is in full compliance with Nasdaq's continued listing rules. The next steps named in the filings are the review of esmethadone, the Phase 2 work on NDV-01 and the Sepranolone trial plans on the dates listed above. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story RLMD Relmada Therapeutics, Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/relmada-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Relmada Therapeutics regains compliance with Nasdaq $1.00 bid price rule", 2025-09-16, https://aibio.space/news/relmada-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/